Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects
- 1 October 1994
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 47 (3) , 247-252
Abstract
The acute and chronic effects on blood coagulation and fibrinolysis of a new molecular weight dermatan sulphate (Desmin 370) have been investigated in a double blind, placebo-controlled cross over study in 12 healthy volunteers. The compound (100 and 200 mg) was injected IM and the expected heparin cofactor II potentiating effect, reflecting dermatan sulphate activity, peaked after 2h and was still detectable after 9 h. Surprisingly for this type of compound, a substantial increase in anti-Xa activity also appeared and lasted up to 12 h in the absence of a significant change in aPTT. The bovine-thrombin time was not changed, while human-thrombin times were slightly, albeit non-significantly, prolonged. The activity of t-PA was increased 6h after the higher dose, but the overall pattern of fibrinolytic activities did not suggest any important change after drug treatment in comparison to placebo. No residual or cumulative effect on any of the investigated parameters was detectable 24h after the injection on the 4th and 8th days during repeated daily administration. Parallel in vitro and in vivo investigations showed that the unexpected anti-Xa effect was not attributable to contamination by traces of low molecular weight heparin. Desmin 370, a low molecular weight dermatan sulphate that potentiates heparin cofactor II and also inhibits Factor Xa, deserves clinical evaluation as an antithrombotic agent.Keywords
This publication has 25 references indexed in Scilit:
- Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfateThrombosis Research, 1993
- Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbitThrombosis Research, 1992
- Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteersThrombosis Research, 1991
- PHARMACOLOGIC PROPERTIES OF A LOW-MOLECULAR-WEIGHT DERMATAN SULFATE - COMPARISON WITH UNFRACTIONATED DERMATAN SULFATE1990
- Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in VivoAnnals of the New York Academy of Sciences, 1989
- Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan SulfateaAnnals of the New York Academy of Sciences, 1989
- 35 Acute effects of dermatan sulfate on fibrinolysis in healthy volunteersFibrinolysis, 1988
- Antithrombotic Properties of Dermatan Sulphate in a Rat Venous Thrombosis ModelPathophysiology of Haemostasis and Thrombosis, 1987
- Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan SulfateSeminars in Thrombosis and Hemostasis, 1985
- HEPARAN-SULFATE AND DERMATAN SULFATE INHIBIT THE GENERATION OF THROMBIN ACTIVITY IN PLASMA BY COMPLEMENTARY PATHWAYS1984